uploads/2018/08/Diagnostics-segment-2.png

How Is Roche’s Diagnostics Segments Positioned in August?

By

Updated

Centralized Point of Care Solutions Segment revenue trends

In Roche’s Diagnostics division, the Centralized Point of Care Solutions segment reported first-half revenues of 3.76 billion Swiss francs, reflecting ~6.0% YoY growth at CER (constant exchange rates). In the second quarter, Roche’s (RHHBY) Centralized and Point of Care Solutions reported revenues of 2.0 billion Swiss francs, which reflected ~9.0% YoY growth at CER.

In the second quarter, in EMEA, North America, and other regions, its Centralized Point of Care Solutions reported revenues of 694.0 million Swiss francs, 389.0 million Swiss francs, and 956.0 million Swiss francs, respectively, reflecting ~3.0%, 6.0%, and 15.0% growth on a YoY basis at CER.

Diagnostics segment

Article continues below advertisement

Molecular diagnostics segment revenue trends

Roche’s molecular diagnostics unit reported revenues of 511.0 million Swiss francs in the second quarter. This included respective revenues of 190.0 million Swiss francs, 189.0 million Swiss francs, and 132.0 million Swiss francs in the EMEA, North America, and other regions. In the second quarter, Roche’s molecular diagnostics witnessed ~4.0% YoY growth at CER.

In the first half, Roche’s molecular diagnostics reported revenues of 979.0 million Swiss francs, reflecting ~5.0% YoY growth at CER. In EMEA, North America and other regions, molecular diagnostics reported first-half revenues of 379.0 million Swiss francs, 376.0 million Swiss francs, and 224.0 million Swiss francs, respectively, reflecting ~5.0%, 6.%, and 5.% growth on a YoY basis at CER.

Tissue diagnostics segment revenue trends

Roche’s tissue diagnostics unit generated revenues of 290.0 million Swiss francs in the second quarter, reflecting ~15.0% YoY growth at CER. In EMEA, North America, and other regions, Roche’s tissue diagnostics segment reported second-quarter revenues of 74.0 million Swiss francs, 169.0 million Swiss francs, and 47.0 million Swiss francs, respectively, reflecting ~14.0%, ~15.0%, and 15.0% growth on a YoY basis at CER.

Roche’s tissue diagnostics unit reported first-half revenues of 539.0 million Swiss francs. This included revenues of 142.0 million Swiss francs, 310.0 million Swiss francs, and 87.0 million Swiss francs from the EMEA, North America, and other regions, respectively.

Among Roche’s peers in the molecular diagnostics market, Hologic (HOLX), Becton Dickinson (BDX), and Agilent Technologies (A) reported revenues of $824.0 million, $4.3 billion, and $1.2 billion, respectively, in the second quarter.

Advertisement

More From Market Realist